PROCEPT BioRobotics Corporation $PRCT Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp grew its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 105.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,454,434 shares of the company’s stock after purchasing an additional 745,778 shares during the quarter. Mackenzie Financial Corp’s holdings in PROCEPT BioRobotics were worth $51,909,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in PRCT. Alliancebernstein L.P. boosted its holdings in PROCEPT BioRobotics by 0.6% during the second quarter. Alliancebernstein L.P. now owns 2,156,856 shares of the company’s stock worth $124,235,000 after buying an additional 13,163 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in PROCEPT BioRobotics by 23.3% in the third quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company’s stock valued at $70,315,000 after buying an additional 371,798 shares in the last quarter. Chicago Capital LLC increased its holdings in PROCEPT BioRobotics by 175.7% in the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after buying an additional 999,873 shares in the last quarter. Champlain Investment Partners LLC raised its position in shares of PROCEPT BioRobotics by 34.3% in the third quarter. Champlain Investment Partners LLC now owns 1,437,897 shares of the company’s stock worth $51,319,000 after acquiring an additional 367,251 shares during the period. Finally, Artisan Partners Limited Partnership boosted its stake in shares of PROCEPT BioRobotics by 38.4% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,365,099 shares of the company’s stock worth $48,720,000 after acquiring an additional 378,844 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Down 6.0%

PRCT opened at $26.12 on Friday. The company has a market cap of $1.47 billion, a PE ratio of -15.27 and a beta of 1.02. PROCEPT BioRobotics Corporation has a twelve month low of $19.35 and a twelve month high of $66.85. The company has a 50-day moving average price of $28.78 and a 200 day moving average price of $32.63. The company has a quick ratio of 5.77, a current ratio of 6.85 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The firm had revenue of $76.38 million during the quarter, compared to analyst estimates of $93.70 million. During the same quarter in the previous year, the firm posted ($0.35) earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Sell-side analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director bought approximately $4.28M of PRCT stock, signaling insider confidence in the company. Article Title
• Positive Sentiment: Another director purchase of about $2.42M reported, reinforcing insider accumulation that can support the share price. Article Title
• Positive Sentiment: Company announced the international launch of the HYDROS robotic system (next‑generation Aquablation platform), which expands addressable markets and supports long‑term revenue growth. Article Title
• Neutral Sentiment: Coverage noted a gap‑up in shares following insider buying, indicating short‑term market reaction to the purchases but not resolving broader concerns. Article Title
• Negative Sentiment: Levi & Korsinsky flagged an alleged $50.2M adjusted EBITDA loss versus a previously projected $35M, and is investigating — this raises concerns about financial reporting and could pressure the stock. Article Title
• Negative Sentiment: Pomerantz LLP announced an investor investigation into PRCT, signaling potential litigation or shareholder claims that could drive legal costs and uncertainty. Article Title
• Negative Sentiment: An EVP, Alaleh Nouri, sold 3,243 shares (~$83k) and reduced ownership ~2.8% — insider selling can be interpreted negatively, though the size is modest relative to the director buys. SEC filing: Form 4

Analyst Ratings Changes

A number of research firms have recently commented on PRCT. Wall Street Zen cut PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Robert W. Baird began coverage on PROCEPT BioRobotics in a research report on Friday, March 6th. They set a “neutral” rating and a $30.00 price target on the stock. Wells Fargo & Company dropped their price objective on PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a report on Thursday, February 26th. Finally, Truist Financial cut their price objective on PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $40.82.

Insider Transactions at PROCEPT BioRobotics

In other news, Director Antal Rohit Desai purchased 98,699 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $24.55 per share, for a total transaction of $2,423,060.45. Following the completion of the transaction, the director owned 426,262 shares of the company’s stock, valued at $10,464,732.10. This trade represents a 30.13% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kevin Waters sold 6,721 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $23.70, for a total value of $159,287.70. Following the completion of the transaction, the executive vice president owned 152,264 shares in the company, valued at $3,608,656.80. The trade was a 4.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have bought 426,262 shares of company stock valued at $10,483,091 and have sold 16,856 shares valued at $405,811. Corporate insiders own 6.60% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.